SuperworthInsight Molecular Diagnostics shares outstanding IMDX
Diluted shares outstanding, averaged over each quarter, from 2015.
- Latest quarter, to Jun 30, 2026
- 36.8M
- On a year earlier
- +14.8%
- more shares
Insight Molecular Diagnostics had 36.8M diluted shares outstanding on average in Q2 FY26, the quarter to Jun 30, 2026.
That is 14.8% more than a year earlier, so each share owns a little less of the company.
Shares outstanding over time
Fiscal year by fiscal year
| Fiscal year | Shares, fourth quarter | Change |
|---|---|---|
| FY2025 | 32.1M | +84% |
| FY2024 | 17.4M | +110% |
| FY2023 | 8.3M | +39% |
| FY2022 | 5.9M | +29% |
| FY2021 | 4.6M | +37% |
| FY2020 | 3.4M | +24% |
| FY2019 | 2.7M | +34% |
| FY2018 | 2M | +29% |
| FY2017 | 1.6M | +10% |
| FY2016 | 1.4M | +17% |
| FY2015 | 1.2M | n/a |
Each fiscal year is the twelve months to its fourth quarter, shown as the fourth quarter's average share count.
Quarter by quarter
| Quarter | Ended | Shares outstanding | On a year earlier |
|---|---|---|---|
| Q2 FY26 | 36.8M | +15% | |
| Q1 FY26 | 34.5M | +34% | |
| Q4 FY25 | 32.1M | +84% | |
| Q3 FY25 | 32M | +134% | |
| Q2 FY25 | 32M | +149% | |
| Q1 FY25 | 25.7M | +211% | |
| Q4 FY24 | 17.4M | +110% | |
| Q3 FY24 | 13.7M | +66% | |
| Q2 FY24 | 12.9M | +59% | |
| Q1 FY24 | 8.3M | +138488% | |
| Q4 FY23 | 8.3M | +39% | |
| Q3 FY23 | 8.3M | +39% |
What the shares outstanding tells you
Diluted shares outstanding, averaged over the period. Fewer shares means each one owns more of the company.
A falling count usually means buybacks. A rising one means stock pay, acquisitions paid in shares or new shares sold.
More on Insight Molecular Diagnostics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.